Jason Coloma Sells 34,501 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the transaction, the chief executive officer owned 23,337 shares of the company’s stock, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock traded up $1.45 during trading on Thursday, hitting $31.26. The stock had a trading volume of 575,498 shares, compared to its average volume of 717,789. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 12 month low of $10.98 and a 12 month high of $53.65. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -12.36 and a beta of 2.14. The business’s 50-day moving average is $25.81 and its 200 day moving average is $35.73.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MAZE has been the topic of a number of recent research reports. JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Wedbush raised their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Finally, HC Wainwright increased their target price on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new position in shares of Maze Therapeutics during the first quarter valued at about $917,000. Bank of America Corp DE grew its stake in shares of Maze Therapeutics by 961.3% in the first quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock worth $5,823,000 after purchasing an additional 176,703 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after purchasing an additional 1,383 shares during the last quarter. Exome Asset Management LLC purchased a new position in Maze Therapeutics during the 1st quarter valued at about $2,642,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Maze Therapeutics by 111.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after purchasing an additional 7,673 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.